Investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer.
- Metastatic Castration Resistant Prostate Cancer not previously treated in that setting
- Rising PSA
- High risk for early failure on enzalutatmide
Eligibility will be assessed based on screening GaPSMA PET and FDG PET. Once eligible you will be randomised to enzaluatamide alone or enzalutamide with LuPSMA. LuPSMA is a nuclear medicine targeted therapy. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.